Impella gains a trio of regulatory approvals
Ngày 12/01/2022 03:27 | Lượt xem: 148

Regulators in three countries have granted approvals to Impella surgical products. In the USA, the Food and Drug Administration (FDA) has granted an Early Feasibility Study (EFS) Investigational Device Exemption (IDE) to Impella BTR (Bridge-to-Recovery). In Asia, Impella 5.5 with SmartAssist has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and Hong Kong’s Medical Device Division (MDD).

Impella 5.5 with SmartAssist is a minimally invasive, forward flow, fully unloading heart pump designed by and for heart surgeons with direct or axillary insertion. It received FDA post-market approval (PMA) two years ago. Since then, it has been used to treat more than 4,000 US patients for indications that include AMI cardiogenic shock, cardiomyopathy and post-cardiotomy cardiogenic shock. Historically, the cardiogenic shock survival rate has been approximately 50%. Impella 5.5 with SmartAssist patients have a 74% survival to explant, with 59% of surviving patients achieving native heart recovery.

In Japan, Impella 5.5 with SmartAssist is now indicated for use in the treatment of drug-resistant acute heart failure attributable to causes such as cardiogenic shock. The first Impella 5.5 with SmartAssist patient in Japan is expected to be treated in the coming months.

“The Japanese market is ideal for Impella 5.5 with SmartAssist because the technology provides minimally invasive, longer-term unloading support, enabling native heart recovery in a country that is more resistant to invasive sternotomies and heart transplants,” said Michael R Minogue, Abiomed’s chairman, president and chief executive officer.

In the USA, the FDA has approved the Impella BTR early feasibility IDE study, clearing the way for the first patient in the world to be treated with Impella BTR. Impella BTR is a percutaneous heart pump, with greater than six litres of blood flow per minute. It is designed to be much less invasive than current LVADs.

The vision of the Impella BTR development program is to provide a patient with home discharge and up to one year of full haemodynamic support. In the early feasibility study, ten patients will be enrolled at up to five hospitals and supported by Impella BTR for up to 28 days. The first Impella BTR patient is expected to be treated in March or April this year.

“The FDA’s approval is a first step toward making this longer-term minimally invasive forward flow smart heart pump a reality for patients with chronic heart failure,” said Minogue.

Impella BTR is an investigational device, limited by federal law to investigational use only.

Source CardiovascularNews

Duc Tin Clinic

Print Chia sẽ qua facebook bài: Impella gains a trio of regulatory approvals Chia sẽ qua google bài: Impella gains a trio of regulatory approvals Chia sẽ qua twitter bài: Impella gains a trio of regulatory approvals Chia sẽ qua MySpace bài: Impella gains a trio of regulatory approvals Chia sẽ qua LinkedIn bài: Impella gains a trio of regulatory approvals Chia sẽ qua stumbleupon bài: Impella gains a trio of regulatory approvals Chia sẽ qua icio bài: Impella gains a trio of regulatory approvals Chia sẽ qua digg bài: Impella gains a trio of regulatory approvals Chia sẽ qua yahoo bài: Impella gains a trio of regulatory approvals Chia sẽ qua yahoo bài: Impella gains a trio of regulatory approvals Chia sẽ qua yahoo bài: Impella gains a trio of regulatory approvals Chia sẽ qua yahoo bài: Impella gains a trio of regulatory approvals

Tin tức liên quan

CUSTOMER REVIEWS

  • I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

    I sincerely thank you !. Tel: 0938303275

  • Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

    Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

  • As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

  • The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

  • I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search
Customer support

    Phone: (028) 3981 2678
    Mobile: 0903 839 878 - 0909 384 389

TOP